c-Kit (D820Y)

KIT · Variant type: point · HGVS: p.D820Y

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ripretinib	99.4%	0.6%	92.95
2	Pacritinib	98.9%	1.1%	88.64
3	Tivozanib	98.5%	1.5%	92.42
4	Pralsetinib	98.3%	1.7%	93.43
5	Dasatinib	98.3%	1.7%	87.97
6	Ponatinib	98.0%	2.0%	78.23
7	Nintedanib	97.9%	2.1%	90.23
8	Erdafitinib	97.6%	2.4%	95.71
9	Axitinib	97.3%	2.7%	93.23
10	Avapritinib	97.2%	2.8%	97.73
11	Brigatinib	96.6%	3.4%	82.96
12	Apatinib	96.3%	3.7%	97.73
13	Lenvatinib	96.1%	3.9%	97.74
14	Nilotinib	95.8%	4.2%	96.49
15	Cabozantinib	95.4%	4.6%	92.73
16	Vemurafenib	95.3%	4.7%	96.49
17	Selpercatinib	94.4%	5.6%	96.72
18	Regorafenib	94.0%	6.0%	95.99
19	Quizartinib	93.4%	6.6%	99.50
20	Sunitinib	93.3%	6.7%	91.73
21	Sorafenib	93.2%	6.8%	96.72
22	Fedratinib	90.2%	9.8%	96.21
23	Bosutinib	88.0%	12.0%	87.22
24	Gilteritinib	87.2%	12.8%	88.97
25	Fostamatinib	86.7%	13.3%	96.74

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ripretinib	99.4%	—	—
Pacritinib	98.9%	—	—
Tivozanib	98.5%	—	—
Pralsetinib	98.3%	—	—
Dasatinib	98.3%	—	—
Ponatinib	98.0%	—	—
Nintedanib	97.9%	—	—
Erdafitinib	97.6%	—	—
Axitinib	97.3%	—	—
Avapritinib	97.2%	—	—
Brigatinib	96.6%	—	—
Apatinib	96.3%	—	—
Lenvatinib	96.1%	—	—
Nilotinib	95.8%	—	—
Cabozantinib	95.4%	—	—
Vemurafenib	95.3%	—	—
Selpercatinib	94.4%	—	—
Regorafenib	94.0%	—	—
Quizartinib	93.4%	—	—
Sunitinib	93.3%	—	—
Sorafenib	93.2%	—	—
Fedratinib	90.2%	—	—
Bosutinib	88.0%	—	—
Gilteritinib	87.2%	—	—
Fostamatinib	86.7%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.2ms